CorMedix (CRMD) closed at $10.76, with Wall Street analysts projecting a mean price target of $19.43, implying an 80.6% upside. Despite general skepticism regarding the reliability of price targets, CRMD exhibits strong analyst agreement on upward earnings estimate revisions, evidenced by a 1.1% increase in the Zacks Consensus Estimate over the past 30 days, and holds a Zacks Rank #1 (Strong Buy), collectively indicating a potential for near-term stock appreciation.
CorMedix (CRMD) closed at $10.76, having gained 0.3% over the past four weeks, with Wall Street analysts projecting a mean price target of $19.43, indicating an 80.6% upside potential. This consensus is derived from seven short-term targets ranging from $14.00 to $22.00, with a standard deviation of $2.94, suggesting a relatively tight clustering of estimates. While the article notes general skepticism regarding the reliability of price targets due to potential analyst bias, CRMD presents a more robust bullish signal through strong agreement on upward earnings estimate revisions. The Zacks Consensus Estimate for the current year has increased by 1.1% over the last 30 days, with one estimate moving higher and no negative revisions. This positive trend in earnings estimate revisions is empirically correlated with near-term stock price movements, providing a legitimate reason for expected upside. Furthermore, CRMD holds a Zacks Rank #1 (Strong Buy), placing it in the top 5% of stocks based on earnings estimates, which is considered a more conclusive indicator of potential near-term appreciation.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.70
Ticker Sentiment
